Cowen & Co
http://www.cowen.com/default.htmlCowen and Company offers investment banking services, including equity research, equity and convertible debt financings, mergers and acquisitions advisory services, and restricted security sales.
-
Adaptimmune Provides Q4 and Full Year 2024 Business Update
-
Adaptimmune Therapeutics (ADAP) Secures up to $125 Million Debt Financing with Hercules Capital
-
Adaptimmune Secures up to $125 Million Debt Financing with Hercules Capital
-
Adaptimmune (ADAP) and TCR2 (TCRR) to Merge
-
Adaptimmune and TCR² Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors
-
Adaptimmune and TCR² Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors
-
Adaptimmune and TCR2 Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors
-
Adaptimmune Therapeutics plc Announces Closing of Public Offering of American Depositary Shares
-
Adaptimmune Therapeutics (ADAP) Prices 20.5M ADS Offering at $11/ADS
-
Adaptimmune Therapeutics plc Prices Public Offering of American Depositary Shares
-
Adaptimmune Therapeutics (ADAP) Announces Proposed 12.5M ADS Offering
-
Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares
-
Adaptimmune Therapeutics plc Announces Full Exercise and Closing of Underwriters’ Option to Purchase Additional American Depositary Shares
-
Adaptimmune Therapeutics plc Announces Closing of Public Offering of American Depositary Shares
-
Adaptimmune Therapeutics (ADAP) Prices 21 Million Offering at $4/ADS
-
Adaptimmune Therapeutics plc Prices Public Offering of American Depositary Shares
-
Adaptimmune Therapeutics (ADAP) Plans Offering of ADSs
-
Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares
-
Adaptimmune Therapeutics plc Announces Closing of Public Offering and Exercise of Underwriters’ Option to Purchase Additional American Depositary Shares
-
Adaptimmune Therapeutics (ADAP) Prices 14.3M Offering at $4.20/ADS
-
Adaptimmune Therapeutics plc Prices Public Offering of American Depositary Shares
-
Adaptimmune Therapeutics (ADAP) Plans Offering of American Depositary Shares
-
Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares
-
Adaptimmune to Present at the Cowen and Company 37th Annual Health Care Conference
-
Adaptimmune to Present at Cowen and Company’s 36th Annual Health Care Conference
-
Cowen Starts Adaptimmune Therapeutics plc (ADAP) at Outperform
-
Adaptimmune Announces Closing of Initial Public Offering
-
Adaptimmune Therapeutics (ADAP) IPO Opens Up 13%
-
Adaptimmune Therapeutics (ADAP) Prices 11.25M IPO at $17/ADS
-
Adaptimmune Announces Pricing of Initial Public Offering
-
Adaptimmune Therapeutics (ADAP) Files $150M IPO

